Indian Stock Market 2025 Review: Sectors That Outperformed Nifty 50
Discover the top-performing sectors in the Indian stock market for 2025, including PSU banks, metals, and auto stocks, and learn how to make informed investment decisions.
Discover the top-performing sectors in the Indian stock market for 2025, including PSU banks, metals, and auto stocks, and learn how to make informed investment decisions.
The US stock market is closed today for the New Year holiday, but what does this mean for Indian investors? Get the latest updates on the impact of US market closures on Indian markets and global trading trends.
E to E Transportation is set to make its market debut on Jan. 2, 2026, with a potential bumper listing, as indicated by Grey Market Premium trends, which suggest over 90% gains.
MOIL Ltd has revised manganese ore prices for January 2026, with Ferro grades increasing by 3%. What does this mean for investors and the Indian stock market?
The combination of GST and cess levy on pan masala manufacturing is set to create a comprehensive tax architecture, reducing evasion and protecting tax revenue. Learn how this move will impact the Indian economy and what it means for investors.
Get the latest updates on gold and silver prices in India, including market trends, expert analysis, and investment strategies for 2026.
Vodafone Idea receives a GST penalty order of about Rs 638 crore. What are the implications for investors and the telecom sector? Learn more about the ongoing developments.
The Reserve Bank of India has expressed concerns over the rising structural pressures in the insurance sector, driven by high-cost distribution strategies. What does this mean for Indian investors and the future of the insurance industry?
Ola Electric Mobility Ltd. reported vehicle registrations of 9,020 units in December, with increased market share to 9.3%, driven by its focused service transformation programme, Hyperservice.
Aurobindo Pharma strengthens its position in the domestic pharmaceutical market with the acquisition of Khandelwal Laboratories’ non-oncology business, expanding its pain management and anti-infective portfolios.